Product Description: Silmitasertib sodium salt is an orally bioavailable, highly selective and potent CK2 inhibitor, with IC50 values of 1 nM against CK2α and CK2α'.
Applications: Cancer-Kinase/protease
Formula: C19H11ClN3NaO2
Citations: Cancer Cell Int. 2024 Dec 26;24(1):432./Int J Mol Sci. 2021 Jan 15;22(2):E819./Metabolism. 2024 Nov 7:162:156060./Oncotarget. 2016 Aug 16;7(33):53191-53203./Autophagy. 2024 Aug 22./Biochem Biophys Res Commun. 2020 Oct 20;531(3):409-415./Biomed Pharmacother. 2024 Jul 29:178:117191./bioRxiv. 2023 Oct 23./bioRxiv. 2024 Jul 25:2024.07.25.605073./bioRxiv. 2024 Nov 6:2024.11.04.621884./Cancer Biol Ther. 2025 Dec;26(1):2457777./Cancers (Basel). 2021, 13(5), 1127./Cell Death Dis. 2024 Mar 16./Cell Death Discov. 2024 Apr 22;10(1):185./Cell Mol Biol Lett. 2023 Oct 24;28(1):85./Cell Rep Methods. 2023 Oct 23;3(10):100599./Cell Rep. 2023 Apr 3;42(4):112339./Cell Stem Cell. 2023 Apr 6;30(4):450-459.e9./Cells. 2021 Jan 18;10(1):E181./Drug Res (Stuttg). 2024 Mar 20./Electronic Theses and Dissertations. 2023 Jul./EMBO Mol Med. 2020 Aug 7;12(8):e11987./Heliyon. 2024 Aug 18;10(16):e36205./Immunol Cell Biol. 2024 Nov 28./Int J Biol Macromol. 2024 Dec 2:138305./Int J Mol Sci. 2020 Mar 3;21(5):1718. /Invest Ophthalmol Vis Sci. 2022 Dec 1;63(13):14./J Biol Chem. 2024 Sep 30:107848./J Immunol. 2023 Mar 27;ji2200598./J Med Chem. 2023 Mar 6./J Med Chem. 2023 Mar 8./Nat Cell Biol. 2021 Mar;23(3):257-267./Nat Commun. 2023 Feb 9;14(1):731./Nat Commun. 2024 Oct 16;15(1):8912./Oncogene. 2017 Aug 24;36(34):4943-4950./Oncogene. 2022 Jan;41(4):571-585./Oncol Rep. 2017 Feb;37(2):1141-1147. /Patent. US20180263995A1./Research Square Preprint. 2023 May 26./Research Square Preprint. 2023 Oct 27./Sci Transl Med. 2018 Jul 18;10(450):eaaq1093./Science. 2017 Dec 1;358(6367):eaan4368./Signal Transduct Target Ther. 2023 May 10;8(1):183./University of California. 2023 Feb./University of Concepcion. 2023.
References: [1]Siddiqui-Jain A, et al. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy.
Cancer Res. 2010 Dec 15;70(24):10288-98./[2]Buontempo F, et al. Synergistic cytotoxic effects of PS-341 and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB. Oncotarget. 2016 Jan 12;7(2):1323-40./[3]Chon HJ, et al. The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment of human hematological malignancies. Front Pharmacol. 2015 Mar 31;6:70./[4]Kendall JJ, et al. CK2 blockade causes MPNST cell apoptosis and promotes degradation of β-catenin. Oncotarget. 2016 Aug 16;7(33):53191-53203.
CAS Number: 1309357-15-0
Molecular Weight: 371.75
Compound Purity: 99.92
Research Area: Cancer
Solubility: DMSO : 100 mg/mL (ultrasonic;warming;heat to 60°C)/H2O : 16.67 mg/mL (ultrasonic)
Target: Autophagy;Casein Kinase
Deutsch
English
